We aimed to report and discuss two cases with BAID and BAIT who have used systemic fl uoroquinolone in the light of clinical fi ndings and differences.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Bilateral acute depigmentation of iris (BAID) and bilateral acute iris transillumination (BAIT) have emerged in recent years and although etiology is unclear it has been accused of systemic fl uoroquinolone.
📊
Key Findings & Data:Bilateral acute depigmentation of iris (BAID) and bilateral acute iris transillumination (BAIT) have emerged in recent years and although etiology is unclear it has been accused of systemic fl uoroquinolone.
💡
Conclusion & Impact:We aimed to report and discuss two cases with BAID and BAIT who have used systemic fl uoroquinolone in the light of clinical fi ndings and differences.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Bilateral acute depigmentation of iris (BAID) and bilateral acute iris transillumination (BAIT) have emerged in recent years and although etiology is unclear it has been accused of systemic fl uoroquinolone. We aimed to report and discuss two cases with BAID and BAIT who have used systemic fl uoroquinolone in the light of clinical fi ndings and differences.
Özet
Bilateral akut iris depigmentasyonu (BAİD) ve transilluminasyonu (BAİT) başlığı altında toplanan iris değişiklikleri son yıllarda gündeme gelmiş ve etiyoloji net olmasa da ağırlıklı olarak sistemik fl orokinolon kullanımı suçlanmıştır. Biz de sistemik fl orokinolon hikayesi olan BAİD ve BAİT gelişen iki ayrı olguyu klinik farklılıkları da tartışarak sunmak istedik.
🔖
Cite This Article
ÖZGE, G., BAYER, A., MUMCUOĞLU, T. (2017). Two Cases Who Were Diagnosed Bilateral Acute Iris Changes Due to Systemic Fluoroquinolone. Glokom Katarakt, Cilt: 12 - Sayı: 2, 137–140. https://ajindex.com/articles/226431
References (9)
Tugal-Tutkun I, Urgancioglu M. Bilateral acute depigmentation of the iris. Graefes Arch Clin Exp Ophthalmol. 2006;244(6):742-6.
Tugal-Tutkun I, Onal S, Garip A, Taskapili M, Kazokoglu H, Ka- dayifcilar S,Kestelyn P. Bilateral acute iris transillumination. Arch Ophthalmol. 2011;129(10):1312-9.
Knape RM, Sayyad FE, Davis JL. Moxifl oxacin and bilateral acute iris transillumination. J Ophthalmic Infl amm Infect. 2013;14:10. Morshedi RG, Bettis DI, Moshirfar M, Vitale AT. Bilateral acute iris transillumination following systemic moxifl oxacin for respira- tory illness: report of two cases and review of the literature. Ocul Immunol Infl amm. 2012;20(4):266-72.
Tranos P, Nasr MB, Asteriades S, Vakalis A, Georgalas I. Bilateral diffuse iris atrophy after the use of oral clarithromycin. Cutan Ocul Toxicol. 2014;33(1):79-81.
Gonul S, Bozkurt B. Bilateral acute iris transillumination (BAIT) initially misdiagnosed as acute iridocyclitis. Arq Bras Oftalmol. 2015;78(2):115-7.
Hinkle DM, Dacey MS, Mandelcorn E, Kalyani P, Mauro J, Bates JH, Soukasian SH, Holland GN, Foster CS, Fraunfelder FT, Davis JL, Fraunfelder FW. Bilateral uveitis associated with fl uoroquino- lone therapy. Cutan Ocul Toxicol. 2012;31(2):111-6.
Wefers Bettink-Remeijer M, Brouwers K, van Langenhove L, De Waard PW, Missotten TO, Martinez Ciriano JP, Van Aken E. Uve- itis-like syndrome and iris transillumination after the use of oral moxifl oxacin. Eye (Lond). 2009;23(12):2260-2.
Hariprasad SM, Shah GK, Mieler WF, Feiner L, Blinder KJ, Ho- lekamp NM, Gao H,Prince RA. Vitreous and aqueous penetration of orally administered moxifl oxacin in humans. Arch Ophthalmol. 2006;124(2):178-82.
Hariprasad SM, Blinder KJ, Shah GK, Apte RS, Rosenblatt B, Holekamp NM, Thomas MA, Mieler WF, Chi J, Prince RA. Pe- netration pharmacokinetics of topically administered 0.5% moxif- loxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol. 2005;123(1):39-44.